Skip to main content
SpringerLink
Log in

Neurogenic Mechanisms in Prehypertension and Pharmacologic Approaches to the Prevention and Treatment of Hypertension: Highlights of Professor Stevo Julius’ Scientific Contributions

  • Chapter
  • First Online:
Prehypertension and Cardiometabolic Syndrome

Part of the book series: Updates in Hypertension and Cardiovascular Protection ((UHCP))

Abstract

Professor Stevo Julius’ extraordinary scientific contributions during the past half-century advanced our understanding on the pathogenesis, prevention, and treatment of hypertension. His early work showed a relationship between anger, increased sympathetic drive, and reduced parasympathetic tone was fundamental to hyperkinetic borderline hypertension. The investigators provided evidence that sympathetic overactivity led to β-adrenoceptor downregulation and structural and functional cardiac and vascular changes. These changes, rather than autoregulation, contributed to the transition from high to normal cardiac output with a progressive rise in blood pressure. Through population-based studies, Professor Julius confirmed a key role for sympathetic activation, especially faster heart rates, in the early phase of hypertension. Faster heart rates coincided with cardiometabolic abnormalities including hyperinsulinemia, insulin resistance, and dyslipidemia. The investigators subsequently showed that increased vascular α-adrenergic tone induced resistance to insulin-mediated glucose disposal in skeletal muscle. Professor Julius and colleagues documented that angiotensin-receptor blockade safely lowered blood pressure in prehypertensives and slowed the transition to hypertension. He then partnered with long-term colleagues on multinational studies in middle-aged and older hypertensives at high cardiovascular risk. These studies showed that (1) failure to control blood pressure during the first 6 months of a clinical trial led to a significant increase in cardiovascular events, (2) patients controlled on more antihypertensive medications had less benefit of treatment than individuals controlled on monotherapy, and (3) faster heart rates were associated with worse outcomes in treated hypertensives. Clinicians are better prepared to prevent and treat hypertension by understanding the life work of Dr. Julius and colleagues.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 189.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Harburg E, Julius S, McGinn NF, McLeod J, Hoobler SW. Personality traits and behavioral patterns associated with systolic blood pressure in college males. J Chronic Dis. 1964;17:405–14.

    Article  CAS  PubMed  Google Scholar 

  2. Schneider R, Egan B, Johnson EH, Drobney H, Julius S. Anger and anxiety in borderline hypertension. Psychosomatic Med. 1986;48:242–8.

    Article  CAS  Google Scholar 

  3. Julius R, Pascual A, London R. Role of parasympathetic inhibition in the hyperkinetic type of borderline hypertension. Circulation. 1971;44:413–8.

    Article  CAS  Google Scholar 

  4. Esler M, Julius S, Randall OS, Ellis CN, Kashima T. Relation of renin status to neurogenic vascular resistance in borderline hypertension. Am J Cardiol. 1975;36:708–15.

    Article  CAS  PubMed  Google Scholar 

  5. Esler M, Julius S, Zweifler A, Randall O, Harburg E, Gardiner H, et al. Mild high-renin essential hypertension: neurogenic human hypertension? N Engl J Med. 1977;296:405–11.

    Article  CAS  PubMed  Google Scholar 

  6. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target organ changes and higher coronary risk. Tecumseh Blood Pressure Study. JAMA. 1990;264:354–8.

    Article  CAS  PubMed  Google Scholar 

  7. Julius S, Gudbrandsson T, Jamerson K, Andersson O. The interconnection between sympathetics, microcirculation, and insulin resistance in hypertension. Blood Press. 1992;1:9–19.

    Article  CAS  PubMed  Google Scholar 

  8. Julius S, Jamerson K. Sympathetics, insulin resistance and coronary risk in hypertension: the ‘chicken-and-egg’ question. J Hypertens. 1994;12:495–502.

    Article  CAS  PubMed  Google Scholar 

  9. Jamerson K, Julius S, Gudbrandsson T, Andersson O, Brant DO. Reflex sympathetic activation induces acute insulin resistance in the human forearm. Hypertension. 1993;21:618–23.

    Article  CAS  PubMed  Google Scholar 

  10. Wilson PWF, Meigs JB. Cardiometabolic risk: a Framingham perspective. Internat J Obes. 2008;32:S17–20.

    Article  CAS  Google Scholar 

  11. Julius S, Nesbitt SD, Egan BM, Weber MA, Michelson EL, Kaciroti N, Black HR, Grimm RH Jr, Messerli FH, Oparil S, Schork MA. Feasibility of treating prehypertension with an angiotensin-receptor blocker. N Engl J Med. 2006;354:1685–97.

    Article  CAS  Google Scholar 

  12. Julius S, Kjeldsen SE, Weber M, Brunner HR, Ekman S, Hannson L, Hau T, Laragh J, McInnes GT, Mitchell L, Plat F, Schork A, Smith B, Zanchetti A. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: The VALUE randomized trial. Lancet. 2004;363:2022–31.

    Article  CAS  PubMed  Google Scholar 

  13. Weber MA, Julius S, Kjedlsen SE, et al. Cardiovascular outcomes in hypertensive patients comparing single-agent therapy with combination therapy. J Hypertens. 2012;30:2213–22.

    Article  CAS  PubMed  Google Scholar 

  14. Julius S, Palatini P, Kjeldsen SE, Zanchetti A, Weber MA, McInnes GT, Brunner HR, Mancia G, Schork MA, Hua TA, Holzhauer B, Zappe D, Majahalme S, Jamerson K, Koylan N. Usefulness of heart rate to predict future cardiac events in treated patients with high-risk systemic hypertension. Am J Cardiol. 2012;109:685–92.

    Article  Google Scholar 

  15. Spielberger CD, Johnson EH, Russell SF, Crane RJ, Jacobs GA, Worden TJ. The experience and expression of anger: construction and validation of an anger expression scale. In: Chesney MA, Rosenman RH, editors. Anger and hostility in cardiovascular and behavioral disorders. New York: Hemisphere/McGraw; 1985. p. 5–30.

    Google Scholar 

  16. Alexander F. Emotional factors in essential hypertension: presentation of a tentative hypothesis. Psychosom Med. 1939;1:175–9.

    Google Scholar 

  17. Marci CD, Glick DM, Loh R, Dougherty DD. Autonomic and prefrontal cortex responses to autobiographical recall of emotions. Cogn Affect Behav Neurosci. 2007;7:243–50.

    Article  PubMed  Google Scholar 

  18. Levy RL, White PD, Stroud WD. Transient tachycardia: prognostic significance alone and in association with transient hypertension. JAMA. 1945;129:585–8.

    Article  Google Scholar 

  19. Lund-Johansen P. Hemodynamic alterations in early essential hypertension: recent advances. In: Gross F, Strassen, editors. Mild hypertension: recent advances. New York, NY: Raven Press; 1983. p. 237–49.

    Google Scholar 

  20. Julius S, Randall OS, Esler MD, Kashima T, Ellis C, Bennett J. Altered cardiac responsiveness and regulation in the normal cardiac output type of borderline hypertension. Circ Res. 1975;36(6 Suppl 1):199–207.

    Article  CAS  PubMed  Google Scholar 

  21. Messerli FH, Ventura HO, Resisin E, Dreslinski GR, Dunn FG, MacPhee AA, Frohlich ED. Borderline hypertension and obesity: two prehypertensive states with elevated cardiac output. Circulation. 1982;66:55–60.

    Article  CAS  PubMed  Google Scholar 

  22. Reisin E, Messerli FG, Ventura HO, Frohlich ED. Renal hemodynamic studies in obesity hypertension. J Hypertens. 1987;5:397–400.

    CAS  PubMed  Google Scholar 

  23. Egan BM, Schork NJ, Weder AB. Regional hemodynamic abnormalities in overweight men. Focus on alpha-adrenergic vascular responses. Am J Hypertens. 1989;2(6 Part 1):428–34.

    Article  CAS  PubMed  Google Scholar 

  24. Guyton AC, Coleman TG. Quantitative analysis of the pathophysiology of hypertension. Circ Res. 1969;24(5 Suppl):1–19.

    CAS  PubMed  Google Scholar 

  25. Guyton AC. Dominant role of the kidneys and accessory role of whole-body autoregulationin the pathogenesis of hypertension. Am J Hypertens. 1989;2:575–85.

    Article  CAS  PubMed  Google Scholar 

  26. Julius S, Pascual AV, Reilly K, London R. Abnormalities of plasma volume in borderline hypertension. Arch Intern Med. 1971;127:116–9.

    Article  CAS  PubMed  Google Scholar 

  27. Julius S, Conway J. Hemodynamic studies in patients with borderline blood pressure elevation. Circulation. 1968;38:282–8.

    Article  CAS  PubMed  Google Scholar 

  28. Cohn JN. Relationship of plasma volume changes to resistance and capacitance vessel effects of sympathomimetic amines and angiotensin in man. Clin Sci. 1966;30:267–78.

    CAS  PubMed  Google Scholar 

  29. Kjeldsen SE, Moan A, Petrin J, Weder A, Julius S. Effects of increased arterial epinephrine on insulin, glucose and phosphate. Blood Press. 1996;5:27–31.

    Article  CAS  PubMed  Google Scholar 

  30. Julius R, Pascual A, Abbrecht P, London R. Effect of beta-adrenergic blockade on plasma volume in human subjects. Proc Soc Exp Biol Med. 1972;140:982–5.

    Article  CAS  PubMed  Google Scholar 

  31. Julius S, Majahalme S. The changing face of sympathetic overactivity in hypertension. Ann Med. 2000;32:365–70.

    Article  CAS  PubMed  Google Scholar 

  32. Hart MN, Heistad DD, Brody MJ. Effect of chronic hypertension and sympathetic denervation on wall/lumen ratio of cerebral vessels. Hypertension. 1980;2:419–28.

    Article  CAS  PubMed  Google Scholar 

  33. Bevan RD, Tsuru H, Bevan JH. Cerebral artery mass in the rabbit is reduced by chronic sympathetic denervation. Stroke. 1983;14:393–6.

    Article  CAS  PubMed  Google Scholar 

  34. Mulvany MJ. Small artery remodeling in hypertension. Basic Clin Pharm Toxicol. 2011;110:49–55.

    Article  CAS  Google Scholar 

  35. Egan BM, Schork N, Panis R, Hinderliter A. Vascular structure enhances regional resistance responses in mild hypertension. J Hypertension. 1988;6(1):41–8.

    Article  CAS  Google Scholar 

  36. Folkow B. Physiological aspects of primary hypertension. Physiol Rev. 1982;62:347–503.

    Article  CAS  Google Scholar 

  37. Egan B, Panis R, Hinderliter A, Schork N, Julius S. Mechanism of increased alpha-adrenergic vasoconstriction in human essential hypertension. J Clin Invest. 1987;80:812–7.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Anderson EA, Sinkey CA, Lawton WJ, Mark AL. Elevated sympathetic nerve activity in borderline hypertensive humans: Evidence from direct intraneural recordings. Hypertension. 1989;14:177–83.

    Article  CAS  PubMed  Google Scholar 

  39. Esler M. The sympathetic system and hypertension. Am J Hypertens. 2000;13:99S–105S.

    Article  CAS  PubMed  Google Scholar 

  40. Julius S, Jamerson K, Mejia A, Krause L, Schork N, Jones K. The association of borderline hypertension with target orgnai changes and higher coronary risk. Tecumseh Blood Pressure Study. JAMA. 1990;264:354–8.

    Article  CAS  PubMed  Google Scholar 

  41. De Fronzo RA, Tripathy D. Skeletal muscle insulin resistance is the primary defect in type 2 diabetes. Diabetes Care. 2009;32(Suppl 2):S157–63.

    Article  CAS  Google Scholar 

  42. Pollare T, Lithell H, Selinus I, Berne C. Application of prazosin is associated with an increase of insulin sensitivity in obese patients with hypertension. Diabetologia. 1988;31:415–20.

    Article  CAS  PubMed  Google Scholar 

  43. Berne C, Pollare T, Lithell H. Effects of antihypertensive treatment on insulin sensitivity with special reference to ACE inhibitors. Diabetes Care. 1991;14(Suppl 4):39–47.

    Article  PubMed  Google Scholar 

  44. Jamerson KA, Smith SD, Amerena JV, Grant E, Julius S. Vasoconstriction with norepinrphrine causes less forearm insulin resistance than a reflex sympathetic vasoconstriction. Hypertension. 1994;23(past 2):1006–11.

    Article  CAS  PubMed  Google Scholar 

  45. Lillioja S, Young AA, Culter CL, Ivy JL, Abbott WG, Zawadzki JK, Yki-Järvinen H, Christin L, Secomb TW, Bogardus C. Skeletal muscle capillary density and fiber type are possible determinants of in vivo insulin resistance in man. J Clin Invest. 1987;80:415–24.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. MacMahon S, Peto R, Cutler J, Collins R, Sorlie P, Neaton J, Abbott R, Godwin J, Dyer A, Stamler J. Blood pressure, stroke, and coronary heart disease. Part I, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet. 1990;335:765–74.

    Article  CAS  PubMed  Google Scholar 

  47. Willey JZ, Moon YP, Kahn E, Rodriguez CJ, Rundek T, Cheung K, Sacco FL, Elkind MSV. Population attributable risks of hypertension and diabetes for cardiovascular disease and stroke in the Northern Manhattan Study. J Am Heart Assoc. 2014;3:e001106. https://doi.org/10.1161/JAHA.114.001106.

    Article  PubMed  PubMed Central  Google Scholar 

  48. Hall JE, Brands MW, Zappe DH, Alonso GM. Insulin resistance, hyperinsulinemia, and hypertension: causes, consequences, or merely correlations? Proc Soc Exp Biol Med. 1994;208:317–29.

    Article  Google Scholar 

  49. Howard BV. Insulin resistance and lipid metabolism. Am J Cardiol. 1990;84(Suppl 1A):28J–32J.

    Google Scholar 

  50. Pyorala K, Savolainen E, Kaukola S, Haapakoski J. Plasma insulin as a coronary heart disease risk factor: relationship to the other risk factors and predictive value during 9½ year follow-up of the Helsinki Policemen Study. Actu Med Stand Suppl. 1985;701:38–52.

    CAS  Google Scholar 

  51. Ducimetiere P, Eschwege E, Papoz L, Richard JL, Claude JR, Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980;19:205–10.

    Article  CAS  PubMed  Google Scholar 

  52. Palatini P, Benetos A, Grassi G, Julius S, Kjeldsen SE, Mancia G, Narkiewicz K, Parati G, Pessina AC, Ruilope LM, Zanchetti A. Identification and management of the hypertensive patient with elevated heart rate: Statement of a European Society of Hypertension Consensus Meeting. J Hypertens. 2006;24:603–10.

    Article  CAS  PubMed  Google Scholar 

  53. Valentini M, Julius S, Palatini P, Brook RD, Bard RL, Bisognano JD, Kaciroti N. Attenuation of haemodynamic, metabolic and energy expenditure responses to isoproterenol in patients with hypertension. J Hypertens. 2004;22:1999–2006.

    Article  CAS  PubMed  Google Scholar 

  54. Julius S, Li Y, Brant D, Krause L, Buda AJ. Neurogenic pressor episodes fail to cause hypertension, but do induce cardiac hypertrophy. Hypertension. 1989;13:422–9.

    Article  CAS  PubMed  Google Scholar 

  55. Kjeldsen SE, Gjesdal K, Eide I, Aakesson I, Amundsen R, Foss OP, et al. Increased beta-thromboglobulin in essential hypertension: interactions between arterial plasma adrenaline, platelet function and blood lipids. Actu Med Scund. 1983;213:369–73.

    Article  CAS  Google Scholar 

  56. Kjeldsen SE, Zweifler AM, Petrin J, Wder AB, Julius S. Sympathetic nervous system involvement in essential hypertension: Increased platelet noradrenaline coincides with decreased β-adrenoreceptor responsiveness. Blood Press. 1994;3:164–71.

    Article  CAS  PubMed  Google Scholar 

  57. Palatini P, Julius S. Heart rate and the cardiovascular risk. J Hypertension. 1997;15:3–17.

    Article  CAS  Google Scholar 

  58. Aronow WS, Casey DE, Collins KJ, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and management of high blood pressure in adults. Hypertension. 2017.

    Google Scholar 

  59. Rao A, Pandya V, Whaley-Connell A. Obesity and insulin resistance in resistant hypertension: Implications for the kidney. Adv Chron Kid Dis. 2015;22:211–7.

    Article  Google Scholar 

  60. Kotecha D, Flather MD, Altman DG, et al. Heart rate and rhythm and the benefit of beta-blockers in patients with heart failure. J Am Coll Cardiol. 2017;69:2885–96.

    Article  CAS  PubMed  Google Scholar 

  61. Gheorghiade M, Goldstein S. β-blockers in the post-myocardial infarction patient. Circulation. 2002;106:394–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, University of South Carolina School of Medicine, Greenville, SC, USA

    Brent M. Egan

  2. Care Coordination Institute, Greenville, SC, USA

    Brent M. Egan

Authors
  1. Brent M. Egan
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Brent M. Egan .

Editor information

Editors and Affiliations

  1. Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel

    Reuven Zimlichman

  2. Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA

    Stevo Julius

  3. Emeritus Professor of Medicine, University of Milano-Bicocca, Milan, Italy

    Giuseppe Mancia

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Egan, B.M. (2019). Neurogenic Mechanisms in Prehypertension and Pharmacologic Approaches to the Prevention and Treatment of Hypertension: Highlights of Professor Stevo Julius’ Scientific Contributions. In: Zimlichman, R., Julius, S., Mancia, G. (eds) Prehypertension and Cardiometabolic Syndrome. Updates in Hypertension and Cardiovascular Protection. Springer, Cham. https://doi.org/10.1007/978-3-319-75310-2_35

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-75310-2_35

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-75309-6

  • Online ISBN: 978-3-319-75310-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation